Welcome : Guest

Reata Pharmaceuticals, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Reata Pharmaceuticals, Inc., which is principally a Clinical-Stage Biopharmaceutical Company. Illustrated with 41 tables, the report showcases the company's sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-66289
Price: $2050
Company Type: Public
Pages: 45
Date: January 2017
Market Data Tables: 41

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Table 1: Reata Pharmaceuticals, Inc.'s Revenues by Category (2015) in Percentage for License and Milestone Revenue, AbbVie License Agreement, AbbVie Collaboration Agreement, KHK Agreement, and Others......2
Cardiology......6
Table 2: Cardiovascular Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for ACE Inhibitors, Alpha Blockers, Angiotensin Receptor Blockers, Anti-Arrhythmics, Anti-Thrombotics, Beta Blockers, Calcium Channel Blockers, Cholesterol, GP IIb/IIIa Inhibitors, Vasodilators, and Others......6
Table 3: Cardiology Market by Category in the US (2015) - Percentage Breakdown by Value Sales for ACE Inhibitors, Alpha Blockers, Anti-Arrhythmics, ARB's, Beta Blockers, Calcium Blockers, Cholesterol, Digitalis, Diuretics, Vasodilators, and Others......7
Table 4: Cardiology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Cardiac Rhythm Management & Congestive Heart Failure Devices, Cardiac Surgery, and Interventional Cardiology......8
Pulmonary Arterial Hypertension (PAH)......9
Table 5: Pulmonary Arterial Hypertension (PAH) Treatment by Drug Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Adcirca, Letairis/Volibris, Remodulin, Revatio, Tracleer, Tyvaso and Ventavis......9
Table 6: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy Worldwide (2015) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......10
Table 7: Pulmonary Arterial Hypertension (PAH) Treatment with Macitentan Drug by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Japan, US and Rest of World......11
Table 8: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type Worldwide (2015) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......12
Table 9: Pulmonary Arterial Hypertension (PAH) Treatment by Type Worldwide (2015) - Percentage Breakdown by Value for Inhaled Prostacyclins, Orals (ERAs, PDE5s, Prostacyclins), and Parenteral Prostacyclins......13
Table 10: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type in Europe (2015) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......14
Table 11: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy in Europe (2015) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......15
Table 12: Pulmonary Arterial Hypertension Treatment Market by Product Segment in Japan (2015) - Percentage Share Breakdown by Value for Adcirca, Dorner, Flolan, Procylin, Revatio, and Tracleer......16
Table 13: Pulmonary Arterial Hypertension (PAH) Treatment by Therapy in the US (2015) - Percentage Market Share Breakdown by Value for ERA Monotherapy, PDE-5 Monotherapy and ERA+PDE-5 Combination Therapy......17
Table 14: Pulmonary Arterial Hypertension (PAH) Treatment with Prostacyclin Therapy by Type in the US (2015) - Percentage Market Share Breakdown by Value for Prostacyclin + ERA, Prostacyclin + PDE-5 and Triple Therapy......18
Cancer Drugs......19
Table 15: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......19
Table 16: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......20
Cancer Market......21
Table 17: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others*......21
Table 18: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......22
Table 19: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......23
Table 20: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......24
Table 21: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......25
Table 22: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......26
Table 23: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......27
Table 24: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......28
Cancer Patients......29
Table 25: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......29
Table 26: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......30
Table 27: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......31
Table 28: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......32
Table 29: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......33
Table 30: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......34
Table 31: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......35
Ophthalmology......36
Table 32: Ophthalmology Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Ophthalmic pharmaceuticals, Surgical, and Vision Care......36
Table 33: Ophthalmology Surgery by Age Group in the US (2015) - Percentage Market Share Breakdown by No. of Patients for 45-64 Years, 65+ Years Age, and Others......37
Table 34: Ophthalmology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Cataract & Vitreoretinal Surgery, Ophthalmic Lasers, and Vision Care......38
Cardiology Therapeutics......39
Table 35: Market Shares of Leading Cardiology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......39
Cancer Drugs......40
Table 36: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......40
Table 37: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......41
Table 38: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......42
Table 39: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......43
Table 40: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......44
Ophthalmology Therapeutics......45
Table 41: Market Shares of Leading Ophthalmology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for F. Hoffmann-La Roche AG, Merck Ltd., Novartis AG, Pfizer, Inc., and Others......45